Alnylam Pharmaceuticals (NASDAQ:ALNY) Director Sells $13,729,567.84 in Stock

Key Points

• Dennis A. Ausiello, Director of Alnylam Pharmaceuticals, sold 31,448 shares at an average price of $436.58, significantly reducing his ownership by 97.18%.
• Alnylam Pharmaceuticals reported a surprise earnings per share (EPS) of $0.32, beating the consensus estimate of ($0.54), reflecting a 17.3% year-over-year revenue increase.
• Institutional investors hold 92.97% of Alnylam's stock, with several firms increasing their stakes, indicating strong institutional interest in the company.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) Director Dennis A. Ausiello sold 31,448 shares of the stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the sale, the director owned 911 shares in the company, valued at approximately $397,724.38. The trade was a 97.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Alnylam Pharmaceuticals Stock Up 0.0%

Shares of ALNY traded up $0.03 during midday trading on Wednesday, hitting $458.31. The company had a trading volume of 1,223,490 shares, compared to its average volume of 1,367,085. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $466.31. The firm has a market capitalization of $60.08 billion, a P/E ratio of -185.55 and a beta of 0.25. The company's 50-day simple moving average is $354.46 and its 200-day simple moving average is $294.11.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. The company had revenue of $773,689 billion for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company's quarterly revenue was up 17.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Bessemer Group Inc. grew its stake in Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the 1st quarter valued at approximately $275,000. GAMMA Investing LLC grew its position in shares of Alnylam Pharmaceuticals by 14.3% during the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock worth $166,000 after buying an additional 77 shares in the last quarter. Brighton Jones LLC bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $243,000. Finally, Silvercrest Asset Management Group LLC acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at $1,151,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Barclays lifted their target price on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a report on Friday, August 1st. UBS Group raised their target price on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a report on Friday, August 1st. BMO Capital Markets boosted their price target on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 24th. Scotiabank increased their price objective on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a "sector outperform" rating in a research note on Friday, August 1st. Finally, Morgan Stanley increased their target price on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Twenty-two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $405.33.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.